Limits...
Toxicity profile of a nutraceutical formulation derived from green mussel Perna viridis.

Chakraborty K, Joseph D, Chakkalakal SJ - Biomed Res Int (2014)

Bottom Line: No test article related mortalities as well as change in body weight, and food and water consumption were observed.Histopathological alterations were not observed in the vital organs of rats.This study demonstrated that the green mussel formulation is safe to consume without any adverse effects in the body.

View Article: PubMed Central - PubMed

Affiliation: Marine Biotechnology Division, Central Marine Fisheries Research Institute, Ernakulam North P.O., PB No. 1603, Cochin, Kerala 682018, India.

ABSTRACT
The short-term (acute) and long-term (subchronic) toxicity profile, mean lethal dose 50 (LD50), and no-observed-adverse-effect level (NOAEL) of a nutraceutical formulation developed from green mussel Perna viridis, which showed in vitro and in vivo anti-inflammatory properties, were evaluated in the present study. The formulation was administered to the male and female Wistar rats at graded doses (0.5, 1.0, and 2.5 g/kg body weight) for two weeks of acute toxicity study and 0.5, 1.0, and 2.0 g/kg body weight for 90 days in subchronic toxicity study. The LD50, variations in clinical signs, changes in body weight, body weight, food/water consumption, organ weight (liver, kidney, spleen, and brain), hematology, serum chemistry, and histopathological changes were evaluated. The LD50 of the formulation was 5,000 mg/kg BW. No test article related mortalities as well as change in body weight, and food and water consumption were observed. No toxicity related significant changes were noted in renal/hepatic function, hematological indices, and serum biochemical parameters between the control and treated groups. Histopathological alterations were not observed in the vital organs of rats. The subchronic NOAEL for the formulation in rats is greater than 2000 mg/kg. This study demonstrated that the green mussel formulation is safe to consume without any adverse effects in the body.

Show MeSH

Related in: MedlinePlus

(a) In vitro anti-inflammatory activities (COXI, II and LOXV inhibition activities) of the green mussel formulation compared with standard anti-inflammatory drugs, aspirin and indomethacin, at different concentrations (0.5, 1, and 5 mg/mL). (b) In vivo anti-inflammatory activity (% difference in paw edema compared to control group) of the green mussel formulation compared to standard anti-inflammatory drug, aspirin.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4066681&req=5

fig1: (a) In vitro anti-inflammatory activities (COXI, II and LOXV inhibition activities) of the green mussel formulation compared with standard anti-inflammatory drugs, aspirin and indomethacin, at different concentrations (0.5, 1, and 5 mg/mL). (b) In vivo anti-inflammatory activity (% difference in paw edema compared to control group) of the green mussel formulation compared to standard anti-inflammatory drug, aspirin.

Mentions: The green mussel formulation (1 mg/mL) showed inhibiting properties against proinflammatory COXII (50%) and LOXV enzymes (47%), and the activities were found to be comparable with standard NSAIDs (Figure 1(a)). In this study, green mussel formulation showed lower inhibition of COXI (41%, 1 mg/mL) than synthetic NSAIDs (>50%). Notably, the animals challenged with the green mussel formulation significantly mitigated (P < 0.05) the carrageenan-induced paw edema in a time-dependent manner till the end of the 6th h as compared to negative control animals throughout the period of study (Figure 1(b)).


Toxicity profile of a nutraceutical formulation derived from green mussel Perna viridis.

Chakraborty K, Joseph D, Chakkalakal SJ - Biomed Res Int (2014)

(a) In vitro anti-inflammatory activities (COXI, II and LOXV inhibition activities) of the green mussel formulation compared with standard anti-inflammatory drugs, aspirin and indomethacin, at different concentrations (0.5, 1, and 5 mg/mL). (b) In vivo anti-inflammatory activity (% difference in paw edema compared to control group) of the green mussel formulation compared to standard anti-inflammatory drug, aspirin.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4066681&req=5

fig1: (a) In vitro anti-inflammatory activities (COXI, II and LOXV inhibition activities) of the green mussel formulation compared with standard anti-inflammatory drugs, aspirin and indomethacin, at different concentrations (0.5, 1, and 5 mg/mL). (b) In vivo anti-inflammatory activity (% difference in paw edema compared to control group) of the green mussel formulation compared to standard anti-inflammatory drug, aspirin.
Mentions: The green mussel formulation (1 mg/mL) showed inhibiting properties against proinflammatory COXII (50%) and LOXV enzymes (47%), and the activities were found to be comparable with standard NSAIDs (Figure 1(a)). In this study, green mussel formulation showed lower inhibition of COXI (41%, 1 mg/mL) than synthetic NSAIDs (>50%). Notably, the animals challenged with the green mussel formulation significantly mitigated (P < 0.05) the carrageenan-induced paw edema in a time-dependent manner till the end of the 6th h as compared to negative control animals throughout the period of study (Figure 1(b)).

Bottom Line: No test article related mortalities as well as change in body weight, and food and water consumption were observed.Histopathological alterations were not observed in the vital organs of rats.This study demonstrated that the green mussel formulation is safe to consume without any adverse effects in the body.

View Article: PubMed Central - PubMed

Affiliation: Marine Biotechnology Division, Central Marine Fisheries Research Institute, Ernakulam North P.O., PB No. 1603, Cochin, Kerala 682018, India.

ABSTRACT
The short-term (acute) and long-term (subchronic) toxicity profile, mean lethal dose 50 (LD50), and no-observed-adverse-effect level (NOAEL) of a nutraceutical formulation developed from green mussel Perna viridis, which showed in vitro and in vivo anti-inflammatory properties, were evaluated in the present study. The formulation was administered to the male and female Wistar rats at graded doses (0.5, 1.0, and 2.5 g/kg body weight) for two weeks of acute toxicity study and 0.5, 1.0, and 2.0 g/kg body weight for 90 days in subchronic toxicity study. The LD50, variations in clinical signs, changes in body weight, body weight, food/water consumption, organ weight (liver, kidney, spleen, and brain), hematology, serum chemistry, and histopathological changes were evaluated. The LD50 of the formulation was 5,000 mg/kg BW. No test article related mortalities as well as change in body weight, and food and water consumption were observed. No toxicity related significant changes were noted in renal/hepatic function, hematological indices, and serum biochemical parameters between the control and treated groups. Histopathological alterations were not observed in the vital organs of rats. The subchronic NOAEL for the formulation in rats is greater than 2000 mg/kg. This study demonstrated that the green mussel formulation is safe to consume without any adverse effects in the body.

Show MeSH
Related in: MedlinePlus